Clinical trial Recruiting at 2 sites Observational Ages 18 to 55

Evaluating thumbtack needle therapy for improving sleep and recovery after surgery

Official title: A Clinical Follow-up Study on the Efficacy of Thumbtack Needle for Postoperative Sleep and Recovery Treatment

Run by The First Affiliated Hospital of Xiamen University · NCT06757023 · Data updated 2026-11-12

This study is testing if thumbtack needle therapy can help women recover better and sleep more soundly after breast cancer surgery.

Quick facts

Study typeObservational
Ages18 Years to 55 Years
SexAll
Enrollment110 (estimated)
SponsorThe First Affiliated Hospital of Xiamen University
Academic / other
Locations2 sites (Xiamen, Fujian and 1 other locations)
StatusRecruiting
StartedNovember 13, 2024
Main results expectedOctober 13, 2026
Study endsNovember 13, 2026
Registry record updatedJanuary 3, 2025
Trial IDNCT06757023 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are women aged 18-55 undergoing breast cancer surgery with general anesthesia and classified as ASA I-II.

Probably not a fit

Patients with severe underlying health conditions or a history of sleep disorders may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the effectiveness of thumbtack needle therapy on postoperative sleep quality and recovery in patients who have undergone general anesthesia for breast cancer surgery. It will focus on understanding how this therapy can prevent sleep disorders and enhance recovery outcomes. The study will include women aged 18-55 who meet specific health criteria and will monitor their postoperative experiences. The findings could provide insights into alternative therapies for managing postoperative complications.

Why it matters

Potential benefit: If successful, this approach could significantly improve sleep quality and recovery times for postoperative patients.

How similar studies have gone: While the specific use of thumbtack needle therapy is novel, similar acupuncture approaches have shown promise in improving postoperative recovery in other studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patients undergoing breast cancer surgery with general anesthesia in the hospital;
2. American Society of Anesthesiologists (ASA) classification I-II;
3. Women aged 18-55 years;
4. No history of chronic insomnia;
5. Individuals who have not taken sedative-hypnotic drugs within the past month.

Exclusion Criteria:

1. Those who do not meet the aforementioned inclusion criteria;
2. A history of severe heart, brain, lung, or kidney diseases (such as acute coronary syndrome (ACS), severe heart failure classified as NYHA Class III or IV, severe arrhythmias, severe valvular disease; acute aortic disease, and severe peripheral vascular disease, etc.), or poor physical condition (including reduced exercise tolerance, multi-organ dysfunction, malnutrition, etc.);
3. A history of sleep disorders and psychiatric history;
4. Inability to receive thumb-tack needle treatment.

Where it's running

  • First Affiliated Hospital of Xiamen University
    Xiamen, Fujian, China
    Recruiting
  • First Affiliated Hospital of Xiamen University
    Xiamen, Fujian, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.